Biography:Ralph DeBerardinis
Ralph J. DeBerardinis | |
|---|---|
| Awards | Paul Marks Prize for Cancer Research; Edith and Peter O'Donnell Award in Medicine |
| Scientific career | |
| Fields | Cancer; Metabolism |
| Thesis | [ProQuest 304449466 Retrotransposition and evolution of L1 sequences in mammalian genomes] (1998) |
| Doctoral advisor | Haig H. Kazazian Jr |
| Other academic advisors | Craig Thompson |
| Website | https://cri.utsw.edu/scientists/ralph-deberardinis-laboratory/ |
Ralph J. DeBerardinis is an American physician-scientist, the chief of the Division of Pediatric Genetics and Metabolism at the Children’s Medical Center Research Institute at UT Southwestern and a professor at the University of Texas Southwestern Medical Center. DeBerardinis became a Howard Hughes Medical Institute Investigator in 2018.[1] DeBerardinis was elected to the National Academy of Medicine in 2020.[2] DeBerardinis is known for his contributions to research on cancer and pediatric inborn errors of metabolism.
Biography
DeBerardinis was born and raised in the Philadelphia area.[3] DeBerardinis received a Bachelor of Science (BS) degree from St. Joseph’s University and M.D. and Ph.D. degrees from the University of Pennsylvania.[4][5] DeBerardinis completed his Ph.D. in the laboratory of Haig H. Kazazian Jr.[6] DeBerardinis was an inaugural trainee of the combined Pediatrics/Genetics Residency program at The Children’s Hospital of Philadelphia (CHOP).[4] DeBerardinis has achieved board certifications in clinical biochemical genetics, medical genetics, and pediatrics.[5] DeBerardinis performed his postdoctoral research in the laboratory of Craig Thompson while he was at the Penn Cancer Center.[7] After completing his postdoctoral work, DeBerardinis opened his own research laboratory in 2008 at University of Texas Southwestern Medical Center.[4][3]
DeBerardinis has been on the Scientific Advisory Boards of several companies, including Agios Pharmaceuticals, Peloton Therapeutics, and Vida Ventures.[3][8] As of April 2022, DeBerardinis has authored over 350 publications and has an h-index of 94.[9]
Scientific contributions
DeBerardinis is well known for his use of isotope-tracing metabolomics to identify how tumors utilize different nutrients. Using genomics and metabolomics approaches, DeBerardinis also has worked to identify novel mutations that affect the activity of metabolic enzymes.[1][10]
Selected awards and honors
- 2017 Outstanding Investigator Award, National Cancer Institute[11]
- 2018 Howard Hughes Medical Institute Investigator[1]
- 2019 TAMEST Edith and Peter O'Donnell Award in Medicine[12]
- 2020 National Academy of Medicine[2]
- 2021 Paul Marks Prize for Cancer Research[7]
Selected publications
- Mullen, Andrew R.; Wheaton, William W.; Jin, Eunsook S.; Chen, Pei-Hsuan; Sullivan, Lucas B.; Cheng, Tzuling; Yang, Youfeng; Linehan, W. Marston et al. (January 2012). "Reductive carboxylation supports growth in tumour cells with defective mitochondria". Nature 481 (7381): 385–388. doi:10.1038/nature10642. PMID 22101431. Bibcode: 2012Natur.481..385M.
- Marin-Valencia, Isaac; Yang, Chendong; Mashimo, Tomoyuki; Cho, Steve; Baek, Hyeonman; Yang, Xiao-Li; Rajagopalan, Kartik N.; Maddie, Melissa et al. (June 2012). "Analysis of Tumor Metabolism Reveals Mitochondrial Glucose Oxidation in Genetically Diverse Human Glioblastomas in the Mouse Brain In Vivo". Cell Metabolism 15 (6): 827–837. doi:10.1016/j.cmet.2012.05.001. PMID 22682223.
- Tasdogan, Alpaslan; Faubert, Brandon; Ramesh, Vijayashree; Ubellacker, Jessalyn M.; Shen, Bo; Solmonson, Ashley; Murphy, Malea M.; Gu, Zhimin et al. (2 January 2020). "Metabolic heterogeneity confers differences in melanoma metastatic potential". Nature 577 (7788): 115–120. doi:10.1038/s41586-019-1847-2. PMID 31853067.
- Hensley, Christopher T.; Faubert, Brandon; Yuan, Qing; Lev-Cohain, Naama; Jin, Eunsook; Kim, Jiyeon; Jiang, Lei; Ko, Bookyung et al. (February 2016). "Metabolic Heterogeneity in Human Lung Tumors". Cell 164 (4): 681–694. doi:10.1016/j.cell.2015.12.034. PMID 26853473.
- Faubert, Brandon; Li, Kevin Y.; Cai, Ling; Hensley, Christopher T.; Kim, Jiyeon; Zacharias, Lauren G.; Yang, Chendong; Do, Quyen N. et al. (October 2017). "Lactate Metabolism in Human Lung Tumors". Cell 171 (2): 358–371.e9. doi:10.1016/j.cell.2017.09.019. PMID 28985563.
References
- ↑ 1.0 1.1 1.2 "Ralph J. DeBerardinis" (in en). https://www.hhmi.org/scientists/ralph-j-deberardinis.
- ↑ 2.0 2.1 "National Academy of Medicine Elects 100 New Members" (in en-US). 2020-10-19. https://nam.edu/national-academy-of-medicine-elects-100-new-members-2020/.
- ↑ 3.0 3.1 3.2 "Ralph DeBerardinis - Scientific Advisory Board Member at Vida Ventures" (in en). https://theorg.com/org/vida-ventures/org-chart/ralph-deberardinis.
- ↑ 4.0 4.1 4.2 "Ralph DeBerardinis Laboratory | Children's Research Institute | Dallas TX" (in en-US). https://cri.utsw.edu/scientists/ralph-deberardinis-laboratory/.
- ↑ 5.0 5.1 children's health. "Biography: Ralph John DeBerardinis, MD". https://www.childrens.com/doctor-profile/ralph-john-deberardinis.
- ↑ DeBerardinis, Ralph John (1998). Retrotransposition and evolution of L1 sequences in mammalian genomes (Thesis). OCLC 187477554. ProQuest 304449466.[page needed][non-primary source needed]
- ↑ 7.0 7.1 "Meet Ralph DeBerardinis, a Recipient of the Paul Marks Prize for Cancer Research | Memorial Sloan Kettering Cancer Center" (in en). 28 February 2022. https://www.mskcc.org/news/meet-ralph-deberardinis-recipient-paul-marks-prize-cancer-research.
- ↑ "Leadership" (in en-US). https://www.agios.com/about-us/leadership/.
- ↑ "Ralph DeBerardinis". https://scholar.google.com/citations?user=Vql9H_cAAAAJ&hl=en.
- ↑ "Ralph DeBerardinis, MD, PhD" (in en). https://www.hhmi.org/2018-investigators/ralph-deberardinis.
- ↑ "2017 Outstanding Investigator Award (OIA) Recipients - National Cancer Institute" (in en). 2018-10-15. https://www.cancer.gov/grants-training/grants-funding/funding-opportunities/oia/award-recipients/2017.
- ↑ "2019 O'Donnell Awards Recipients - TAMEST" (in en-US). https://tamest.org/odonnell-awards/2019/.
 |  |
